Haroon Majoka, MD
Neurology · Bowling Green, KYNPI 1437682978
Payments from drug & device makers
Across 303 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$723
- Pfizer$695
- Neurocrine Biosciences, Inc.$511
- UCB, Inc.$498
- Biogen$296
- Catalyst Pharmaceuticals, Inc.$261
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,34797%
- Education$1503%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 60 | $723 |
| Pfizer | 53 | $695 |
| Neurocrine Biosciences, Inc. | 20 | $511 |
| UCB, Inc. | 18 | $498 |
| Biogen | 17 | $296 |
| Catalyst Pharmaceuticals, Inc. | 11 | $261 |
| Jazz Pharmaceuticals Inc. | 11 | $227 |
| Teva Pharmaceuticals USA, Inc. | 13 | $223 |
| CSL Behring | 13 | $223 |
| AstraZeneca | 4 | $208 |
| Mallinckrodt Hospital Products Inc. | 5 | $165 |
| Novartis | 9 | $138 |
| Argenx US, Inc. | 7 | $137 |
| SK Life Science, Inc. | 6 | $123 |
| Lundbeck LLC | 6 | $118 |
| Eisai Inc. | 4 | $93 |
| Genentech USA, Inc. | 4 | $75 |
| Lilly USA, LLC | 4 | $75 |
| Neurelis, Inc. | 4 | $72 |
| EMD Serono, Inc. | 4 | $72 |
| Amneal Pharmaceuticals LLC | 4 | $61 |
| TG Therapeutics, Inc. | 3 | $54 |
| Cycle Pharmaceuticals Inc | 2 | $51 |
| Sanofi | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Tersera Therapeutics LLC | 2 | $40 |
| ANI Pharmaceuticals, Inc. | 2 | $34 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Octapharma USA, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Livanova USA, Inc. | 1 | $21 |
| Vertex | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Amgen | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Neuropace, Inc. | 1 | $15 |
| Harmony Biosciences LLC | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $13 |
How this compares
$5,497 in reported general payments places this provider in the 55th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 11 | $163,429 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 32 | $30,683 |
| QuliptaAtogepant | 17 | $21,610 |
| UbrelvyUbrogepant | 21 | $21,494 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $16,714 |
| Emgality PenGalcanezumab-Gnlm | 22 | $14,630 |
| Nurtec OdtRimegepant Sulfate | 13 | $13,256 |
| RytaryCarbidopa/Levodopa | 11 | $5,594 |
| Lacosamide | 53 | $3,197 |
| Primidone | 89 | $2,386 |
| Donepezil Hcl | 199 | $2,173 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 79 | $1,886 |
| Gabapentin | 218 | $1,847 |
| Propranolol Hcl ErPropranolol Hcl | 91 | $1,764 |
| Pyridostigmine Bromide | 32 | $1,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $723 | $43,10438 claims |
| PfizerNurtec Odt | $695 | $13,25613 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $61 | $6,87343 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 210 neurology providers in Kentucky.
Other neurology in Bowling Green
- Jianhua ZhuBowling Green$30K
- Eme IgbokweBowling Green$28K
- Wesley ChouBowling Green$27K
- Jae Eun LeeBowling Green$18K
- James MaynardFort Thomas$12.4M
- Gregory JichaLexington$7.1M
- Irene LitvanLouisville$2.7M
- Jenny FengLouisville$2M
- James WinkleyLexington$1.9M
- John SlevinLexington$984K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.